About this episode

This episode explores the UK biotech ecosystem, focusing on the Golden Triangle and the challenges faced by companies in scaling and competitiveness.

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We explore the UK biotech ecosystem : from the Golden Triangle’s evolving role to the challenges of scaling companies, unlocking pension capital and staying globally competitive. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Hakan Goker , Managing Director, M Ventures Maina Bhaman , Partner, Sofinnova Partners Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

People in this episode

Host: Jennifer C. Smith-Parker

Guests: Hakan Goker, Maina Bhaman

Topics covered

• UK biotech
• life sciences investment
• Golden Triangle
• scaling companies
• pension capital
• global competitiveness

Keywords

• UK biotech
• Golden Triangle
• life sciences
• investment ecosystem
• scaling companies
• pension capital
• global competitiveness

Mentioned in this episode

Organizations: M Ventures, Sofinnova Partners

Places: UK, Golden Triangle

More episodes of BioSpace

• The future of pain relief: Exploring opioid alternatives · July 16, 2026 · 19 min
• Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup · July 15, 2026 · 21 min
• Bonus: Q2 2026 Job Market Update · July 14, 2026 · 9 min
• From sequence to scale: Gene editing’s new era in biologics manufacturing · July 10, 2026 · 21 min
• Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil · July 8, 2026 · 17 min
• Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water · July 1, 2026 · 23 min

Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.